NASDAQ: TGTX

TG Therapeutics (TGTX) Stock Analysis & Forecast

Nov 13 close

$64.51−0.05 (−0.1%)

Gekko Brief

AI summaryNov 9 close

TG Therapeutics reported third-quarter 2026 results, with diluted earnings per share of $0.35 against a consensus estimate of $0.26, and revenue of $259.9 million versus an anticipated $245.4 million or $247.2 million depending on source. Net income came in at $55.5 million. U.S. Briumvi net revenue reached $233 million, up 52%, and the company raised its full-year global revenue guidance to $1 billion while pointing to a stronger fourth quarter ahead.

The stock closed at $63.38, up 5.9% on the day, sitting above both its 50-day average of $55.99 and 200-day average of $44.69, with the shorter average above the longer one. It trades near its 52-week high of $63.60. The GekkoIndex reads 45, placing TGTX in the Neutral zone, while the price sits 3.3% above Gekko Fair Value of $61.36.

No confirmed date is on the calendar for the next earnings report. Smart money and unusual options activity show no recorded signals in their respective windows. Seasonality from this point in the calendar has averaged a 13.9% gain over the next 20 trading days across 5 years, rising in 3 of them. Analyst coverage from 3 firms is entirely rated buy, with a consensus target of $69.71, implying 10% upside from current levels. The gap to Gekko Fair Value bears watching given the recent move.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

TG Therapeutics price vs fair value

$65.02$64.51Nov ’25May ’26Nov ’26
Close $64.51200-day averageGekko Fair Value $65.02

TG Therapeutics quick facts

Market cap
$9.75B
P/E ratio
96.4
Forward P/E
30.4
EPS, TTM
$0.67
Revenue, TTM
$897.8M
Profit margin
11.8%
Dividend yield
—
Beta
1.81
Volume
1.10M avg 2.07M
1-year return
+108.0%
Typical daily move
±5.4%
Typical 20-day move
±13.5%
50-day average
$56.70
200-day average
$45.38
Next earnings
Feb 25 before open
Shares outstanding
151.1M
52-week range
$26.76$68.03

TG Therapeutics swing-trade checklist

TG Therapeutics scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $64.51 is above the 50-day ($56.70) and 200-day ($45.38) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    47, Neutral

    Reading 47 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    0.8% below

    Price is within 5% of Gekko Fair Value (0.8% below).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +0.7% on average

    From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

TG Therapeutics stock chart and price history

TG Therapeutics closed at $64.51 on Nov 13, 2026, +108.0% over the past year, inside a 52-week range of $26.76 to $68.03.

Close50-day average200-day averageVolume
TG Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$30$40$50$60DecJan 2026FebMarAprMayJunJulAugSepOctNov64.51

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+15.2%
3 months
+30.9%
6 months
+63.3%
1 year
+108.0%
The full TGTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TGTX in Gekko

Follow TG Therapeutics through every session

Put TGTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track TGTX in GekkoFree for 7 days. No credit card required.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company that has reached the commercial stage, working to acquire, develop and bring to market treatments for B-cell related cancers and autoimmune conditions. It is known for its work on Ublituximab, a glycoengineered monoclonal antibody studied for B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia and relapsing forms of multiple sclerosis, alongside other pipeline candidates aimed at similar patient populations.

Its broader portfolio includes Umbralisib, an oral compound targeting PI3K-delta and CK1-epsilon for use in CLL and lymphoma, Cosibelimab, an antibody aimed at PD-L1, TG-1701, an oral BTK inhibitor, and TG-1801, a bispecific antibody directed at CD47 and CD19. The company also holds licensed preclinical programs covering BET, IRAK4 and GITR, and it works with outside partners on research and development, including Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Novimmune, Ligand Pharmaceuticals, Jubilant Biosys, LFB Biotechnologies, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical and Rhizen Pharmaceuticals.

TG Therapeutics is based in New York City and was established in 1993. Its shares are listed on the NASDAQ under the ticker TGTX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
tgtherapeutics.com

TG Therapeutics GekkoIndex: the smart money zone

TG Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47, in the Neutral zone, down 3.2 points over five sessions.

010047Neutral

Down 3.2 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying17+1.6%+6.4%+11.6%+18.5%
Accumulation201+3.2%+6.2%+9.2%+14.6%
Neutral (current zone)420+0.6%+1.0%+3.5%+11.5%
Distribution61−0.2%−0.3%−1.9%+6.6%
Selling3Too few readings yet

Average TGTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the TGTX price, zone by zone.Track TGTX in Gekko

Is TG Therapeutics stock overvalued? Gekko Fair Value

TG Therapeutics trades 0.8% below Gekko Fair Value of $65.02, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what TG Therapeutics shares are worth, recalculated every trading day.

$65.02

Gekko Fair Value, Nov 14, 2026

0.8% below fair value · About fair value

At the end of Aug 2026 the price was 15.2% below the estimate.

Gekko Fair ValueShare price, month end
$65$65Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open TGTX in Gekko

TG Therapeutics insider and Congress trading

No open-market insider purchases were filed for TG Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for TGTX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every TGTX insider filing, plotted on the chart in Gekko.Open TGTX in Gekko

Congress trades last 90 days

No trades in TGTX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for TGTX, plotted on the chart in Gekko.Open TGTX in Gekko

Buybacks

TG Therapeutics has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$99.99M
As a share of market cap
1.03%

From company filings.

Unusual options activity last 30 days

1signal, 0% of the flagged premium in calls.

Latest: Bearish flow on Nov 11, $284K in unusual premium.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds TGTX.

0added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

TG Therapeutics earnings: next date and track record

TG Therapeutics reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±11.3%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−3.9%Nov ’24+18.4%Mar ’25−19.8%May ’25−18.9%Aug ’25−2.8%Nov ’25+1.4%Feb ’26+19.2%May ’26−6.3%Aug ’26

Last earnings call, Aug 3, 2026 AI summary

What they said
TGTX reported strong Q2 2026 results, exceeding guidance with BRIUMVI approaching a $1 billion annualized revenue run rate. Positive Phase III ENHANCE study results showed a simplified single-dose 600mg initiation schedule. Subcutaneous ublituximab Phase I bioavailability data was positive, with Phase III top-line results expected year-end or early next year. Management is targeting the #1 anti-CD20 therapy position in relapsing MS.
Guidance
Management expects the single-infusion initiation schedule to be available by mid-next year pending approval. Subcutaneous BRIUMVI Phase III top-line results anticipated year-end 2026 or early 2027, potentially doubling the addressable market by entering the self-administered segment.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 3, 2026$0.05
est $0.41
−87.8%$240.3M
est $229.8M
+4.6%−6.3%
May 6, 2026$0.18
est $0.28
−35.7%$204.9M
est $200.3M
+2.3%+19.2%
Feb 26, 2026$0.14
est $0.33
−57.2%$192.6M
est $191.8M
+0.4%+1.4%
Nov 3, 2025$2.43
est $0.24
+912.5%$161.7M
est $193.8M
−16.6%−2.8%
Aug 4, 2025$0.17
est $0.29
−41.4%$141.1M
est $146.3M
−3.5%−18.9%
May 5, 2025$0.03
est $0.17
−82.4%$120.9M
est $134.2M
−9.9%−19.8%
Mar 3, 2025$0.15
est $0.09
+66.7%$108.2M
est $108.8M
−0.6%+18.4%
Nov 4, 2024$0.02
est $0.03
−33.3%$83.88M
est $98.79M
−15.1%−3.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

TG Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for TG Therapeutics is $77.50, +20.1% from the last close, from 6 firms rating the stock in the last 90 days.

$77.50consensus 12-month target, +20.1% from the last close
Low $71High $86
Buy5
Hold0
Sell1

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Bank of America SecuritiesSell, maintained——
Nov 10Evercore ISIBuy, maintained$71+10.1%
Nov 9TD CowenBuy, maintained$75+16.3%
Nov 9J.P. MorganBuy, maintained$72+11.6%
Sep 21H.C. WainwrightBuy, maintained$78+20.9%
+3.5%average 20-day move after past Neutral readings
+0.7%average move over the next 20 trading days in the last 5 years
±5.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

TG Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, TG Therapeutics averaged +0.7% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−42.4%2021+4.0%2022+52.4%2023+3.8%2024+1.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.4%2 of 5
Next 10 trading days−6.8%3 of 5
Next 15 trading days+1.4%1 of 5
Next 20 trading days+0.7%3 of 5
Next 30 trading days+3.7%1 of 5

For scale, TGTX’s typical 20-trading-day move in either direction is about 13.5%.

TG Therapeutics market cap and key statistics

TG Therapeutics’s market cap is $9.75B, with a P/E ratio of 96.4 and revenue of $897.8M over the last twelve months.

Valuation

Market cap
$9.75B
P/E ratio
96.4
Forward P/E
30.4
EPS, TTM
$0.67
Gekko Fair Value
$65.02

Trading

Volume
1.10M
Avg volume, 20 days
2.07M
52-week high
$68.03
52-week low
$26.76
Shares outstanding
151.1M

Financials

Revenue, TTM
$897.8M
Profit margin
11.8%
Return on equity
18%
Quarterly earnings growth, YoY
−85.6%

Risk and income

Beta
1.81
Typical daily move
±5.4%
Typical 20-day move
±13.5%

TG Therapeutics stock news this week

Coverage of TG Therapeutics this week reads positive: 8 positive, 2 neutral and 1 negative headlines.

News sentiment positive

TG Therapeutics peers

TG Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

TG Therapeutics stock FAQ

What is TG Therapeutics’s market cap?

TG Therapeutics’s market cap is $9.75B at the Nov 13, 2026 close of $64.51, with 151.1M shares outstanding. The shares trade on a P/E ratio of 96.4.

What is the TG Therapeutics stock forecast?

The consensus analyst 12-month price target for TG Therapeutics is $77.50, +20.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is TG Therapeutics stock overvalued or undervalued?

On Gekko’s estimate TG Therapeutics is about fair value: the Nov 13, 2026 close of $64.51 is 0.8% below Gekko Fair Value of $65.02. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does TG Therapeutics report earnings next?

TG Therapeutics is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $0.56 per share on revenue of $290.2M. TG Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 11.3% on average across the report.

What is TG Therapeutics’s 52-week high and low?

TG Therapeutics’s 52-week high is $68.03 and its 52-week low is $26.76; it closed at $64.51 on Nov 13, 2026, +108.0% over the past year.

Is TG Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in TG Therapeutics?

Gekko flagged 1 unusual options signal in TG Therapeutics over the last 30 days, with $0 of flagged premium in calls and $284K in puts. The latest, bearish flow, was on Nov 11, 2026 with $284K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See TG Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.